Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Behrens

Showing results (111-120 of 119) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 119 results.
The Journal of Rheumatology|October 13, 2009
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)Dinesh Khanna, Oliver Distler, Jerome Avouac, et al.
The Lancet. Rheumatology|June 26, 2025
Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 studyAndreas Hess, Koray Tascilar, Hanna M Schenker, et al.
Arthritis and Rheumatism|February 13, 2013
Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitisMaria Apel, Steffen Uebe, John Bowes, et al.
Nature Genetics|October 19, 2010
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasisUlrike Hüffmeier, Steffen Uebe, Arif B Ekici, et al.
Therapeutic Advances in Musculoskeletal Disease|September 11, 2023
Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritisOliver FitzGerald, Frank Behrens, Anne Barton, et al.
Lancet (London, England)|February 16, 2024
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trialJuergen Rech, Koray Tascilar, Melanie Hagen, et al.
Nature Communications|February 6, 2015
Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritisJohn Bowes, Ashley Budu-Aggrey, Ulrike Huffmeier, et al.
Nature Communications|February 28, 2025
GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targetsNick Dand, Philip E Stuart, John Bowes, et al.
Medrxiv : the Preprint Server for Health Sciences|October 24, 2023
GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targetsNick Dand, Philip E Stuart, John Bowes, et al.
Pageof 12

Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
The Journal of Rheumatology|October 13, 2009
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)Dinesh Khanna, Oliver Distler, Jerome Avouac, et al.
The Lancet. Rheumatology|June 26, 2025
Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 studyAndreas Hess, Koray Tascilar, Hanna M Schenker, et al.
Arthritis and Rheumatism|February 13, 2013
Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitisMaria Apel, Steffen Uebe, John Bowes, et al.
Nature Genetics|October 19, 2010
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasisUlrike Hüffmeier, Steffen Uebe, Arif B Ekici, et al.
Therapeutic Advances in Musculoskeletal Disease|September 11, 2023
Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritisOliver FitzGerald, Frank Behrens, Anne Barton, et al.
Lancet (London, England)|February 16, 2024
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trialJuergen Rech, Koray Tascilar, Melanie Hagen, et al.
Nature Communications|February 6, 2015
Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritisJohn Bowes, Ashley Budu-Aggrey, Ulrike Huffmeier, et al.
Nature Communications|February 28, 2025
GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targetsNick Dand, Philip E Stuart, John Bowes, et al.
Medrxiv : the Preprint Server for Health Sciences|October 24, 2023
GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targetsNick Dand, Philip E Stuart, John Bowes, et al.
Pageof 12